Danielle Brill
Stock Analyst at Truist Securities
(3.72)
# 787
Out of 5,129 analysts
97
Total ratings
48.28%
Success rate
9.22%
Average return
Main Sectors:
Stocks Rated by Danielle Brill
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CNTA Centessa Pharmaceuticals | Maintains: Buy | $33 → $38 | $23.56 | +61.29% | 3 | Jan 29, 2026 | |
| TECX Tectonic Therapeutic | Maintains: Buy | $64 → $60 | $22.01 | +172.60% | 3 | Jan 8, 2026 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $172 → $169 | $137.44 | +22.96% | 8 | Jan 8, 2026 | |
| IMVT Immunovant | Maintains: Hold | $16 → $22 | $25.94 | -15.19% | 6 | Jan 8, 2026 | |
| HRMY Harmony Biosciences Holdings | Maintains: Buy | $48 → $45 | $36.59 | +22.98% | 9 | Jan 8, 2026 | |
| DNTH Dianthus Therapeutics | Maintains: Buy | $56 → $63 | $49.92 | +26.20% | 2 | Jan 8, 2026 | |
| BBIO BridgeBio Pharma | Maintains: Buy | $80 → $86 | $73.33 | +17.28% | 3 | Jan 8, 2026 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $535 → $530 | $322.28 | +64.45% | 3 | Jan 8, 2026 | |
| PVLA Palvella Therapeutics | Maintains: Buy | $105 → $190 | $79.49 | +139.02% | 4 | Dec 16, 2025 | |
| IRON Disc Medicine | Maintains: Buy | $86 → $114 | $71.99 | +58.36% | 7 | Nov 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $47 | $14.69 | +219.95% | 1 | Oct 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $461.24 | - | 3 | Sep 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $22.07 | +8.74% | 1 | Jul 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Strong Buy | $20 → $52 | $24.11 | +115.68% | 6 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $19.69 | - | 1 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $79 | $60.31 | +30.99% | 1 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $18 | $8.50 | +111.76% | 1 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $150 | $17.96 | +735.19% | 3 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $191.20 | - | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Strong Buy | $605 | $834.55 | -27.51% | 7 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $22.47 | - | 5 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $50 | $42.76 | +16.93% | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $51 | $27.71 | +84.05% | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $180 → $100 | $8.76 | +1,041.55% | 5 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $70.92 | - | 9 | Sep 18, 2023 |
Centessa Pharmaceuticals
Jan 29, 2026
Maintains: Buy
Price Target: $33 → $38
Current: $23.56
Upside: +61.29%
Tectonic Therapeutic
Jan 8, 2026
Maintains: Buy
Price Target: $64 → $60
Current: $22.01
Upside: +172.60%
Neurocrine Biosciences
Jan 8, 2026
Maintains: Buy
Price Target: $172 → $169
Current: $137.44
Upside: +22.96%
Immunovant
Jan 8, 2026
Maintains: Hold
Price Target: $16 → $22
Current: $25.94
Upside: -15.19%
Harmony Biosciences Holdings
Jan 8, 2026
Maintains: Buy
Price Target: $48 → $45
Current: $36.59
Upside: +22.98%
Dianthus Therapeutics
Jan 8, 2026
Maintains: Buy
Price Target: $56 → $63
Current: $49.92
Upside: +26.20%
BridgeBio Pharma
Jan 8, 2026
Maintains: Buy
Price Target: $80 → $86
Current: $73.33
Upside: +17.28%
Alnylam Pharmaceuticals
Jan 8, 2026
Maintains: Buy
Price Target: $535 → $530
Current: $322.28
Upside: +64.45%
Palvella Therapeutics
Dec 16, 2025
Maintains: Buy
Price Target: $105 → $190
Current: $79.49
Upside: +139.02%
Disc Medicine
Nov 10, 2025
Maintains: Buy
Price Target: $86 → $114
Current: $71.99
Upside: +58.36%
Oct 14, 2025
Initiates: Buy
Price Target: $47
Current: $14.69
Upside: +219.95%
Sep 3, 2025
Initiates: Market Perform
Price Target: n/a
Current: $461.24
Upside: -
Jul 21, 2025
Initiates: Buy
Price Target: $24
Current: $22.07
Upside: +8.74%
Dec 10, 2024
Upgrades: Strong Buy
Price Target: $20 → $52
Current: $24.11
Upside: +115.68%
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $19.69
Upside: -
Oct 10, 2024
Reinstates: Outperform
Price Target: $79
Current: $60.31
Upside: +30.99%
Oct 10, 2024
Reinstates: Outperform
Price Target: $18
Current: $8.50
Upside: +111.76%
Oct 10, 2024
Reinstates: Outperform
Price Target: $150
Current: $17.96
Upside: +735.19%
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $191.20
Upside: -
Oct 10, 2024
Reinstates: Strong Buy
Price Target: $605
Current: $834.55
Upside: -27.51%
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $22.47
Upside: -
Oct 10, 2024
Reinstates: Outperform
Price Target: $50
Current: $42.76
Upside: +16.93%
Oct 10, 2024
Reinstates: Outperform
Price Target: $51
Current: $27.71
Upside: +84.05%
Nov 14, 2023
Maintains: Outperform
Price Target: $180 → $100
Current: $8.76
Upside: +1,041.55%
Sep 18, 2023
Downgrades: Underperform
Price Target: n/a
Current: $70.92
Upside: -